SGNTUC-016: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic Her2+ breast cancer
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Scope
National
Locations
Greeley Campus
Harmony Campus
Medical Center of the Rockies
Poudre Valley Hospital
Study ID
Protocol Number: 19-6076
More information available at ClinicalTrials.gov: NCT03975647
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers